Status:
NOT_YET_RECRUITING
Pain Relief After Corneal Collagen Cross-Linking
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Provide Evidence-based Recommendations for Clinicians to Optimize Pain Control After CXL
Eligibility:
All Genders
15-100 years
Phase:
EARLY_PHASE1
Brief Summary
Keratoconus is a progressive corneal ectasia that can lead to significant visual impairment and decreased quality of life. The introduction of corneal cross-linking (CXL) with riboflavin and ultraviol...
Eligibility Criteria
Inclusion
- Patients above the age of 15 years
- Patients who are undergoing CXL treatment
Exclusion
- Renal and/or hepatic failure
- Patients under the age of 15
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT06212830
Start Date
February 1 2024
End Date
August 1 2025
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shamir Medical Center (Assaf Harofeh)
Be’er Ya‘aqov, Israel, 7033001